ViroGym: Realistic Large-Scale Benchmarks for Evaluating Viral Proteins
Organizations: GlaxoSmithKline · Technical University of Munich · University of Washington · KTH Royal Institute of Technology
Abstract
Protein language models (pLMs) have shown strong potential for zero-shot prediction of missense variant effects, yet systematic benchmarking on viral proteins remains limited, a critical gap given the need for proactive tools that can anticipate emerging mutations ahead of experimental validation. Here we introduce ViroGym, a comprehensive benchmark evaluating pLMs across three tasks: 79 deep mutational scanning (DMS) assays covering eukaryotic viruses with 552,065 mutated sequences across 7 phenotypic readouts, 21 influenza neutralisation tasks, and a real-world pandemic prediction task for SARS-CoV-2. We benchmark well-established pLMs on fitness landscapes, antigenic diversity, and pandemic forecasting, and find that the ProGen2 family consistently achieves the strongest performance across all three tasks. Crucially, DMS and neutralisation performance reliably identifies models that generalise to real-world emergence, even though the mutation sets they surface barely overlap, revealing that complementary in vitro benchmarks capture the evolutionary constraints needed for real-world mutation forecasting.
Figures & tables
| Strategy | Recall | Std. | Spearman | Std. |
|---|---|---|---|---|
| masked | 0.1145 | 0.0454 | 0.1089 | 0.1206 |
| wildtype | 0.1123 | 0.0441 | 0.1063 | 0.1157 |
| mutation | 0.1144 | 0.0432 | 0.1083 | 0.1180 |
| grammar | 0.1244 | 0.0452 | 0.1108 | 0.1170 |
| semantic | 0.1382 | 0.0608 | 0.1678 | 0.1045 |
| ratio | 0.0809 | 0.0450 | 0.0912 | 0.0925 |
| Model | Recall | Std. | Spearman | Std. |
|---|---|---|---|---|
| VESPAl | 0.1681 | 0.1279 | 0.2561 | 0.1486 |
| VESPA | 0.1669 | 0.0971 | 0.2380 | 0.1351 |
| Trancept. | 0.1898 | 0.0857 | 0.2735 | 0.1482 |
| ProtGPT2 | 0.1105 | 0.0382 | 0.1019 | 0.0768 |
| ProGen2 | 0.1973 | 0.0913 | 0.2928 | 0.1595 |
| ESM1v | 0.1461 | 0.0667 | 0.1950 | 0.1018 |
| Model Name | Spearman | Std. |
|---|---|---|
| ProtT5 | 0.1961 | 0.206 |
| Tranception | 0.2316 | 0.1696 |
| ProtGPT2 | 0.2018 | 0.1845 |
| ProGen2 | 0.2250 | 0.1852 |
| ESM1v | 0.2282 | 0.2043 |
| ESM1 | 0.2222 | 0.2098 |
| Model Name | Recall | Spearman | Precision@3 |
|---|---|---|---|
| VESPAl | 0.2953 | 0.3158 | 0.00 |
| VESPA | 0.3238 | 0.3616 | 0.00 |
| Tranception L | 0.3743 | 0.4014 | 0.33 |
| ProtGPT2 | 0.0968 | 0.0495 | 0.00 |
| ProGen2 XL | 0.4347 | 0.4018 | 0.33 |
| ESM1v | 0.2676 | 0.2682 | 0.00 |
Appendix figures & tables25 assets
Supplementary material from the paper’s appendix.
Appendix
| Dataset | Phenotype | Sequences | Reference |
| *ZIKV | viral growth | 10,080 | Sourisseau et al. [2019] |
| ZIKV | immune escape | 9,576 | Sourisseau et al. [2019] , Kikawa et al. [2023] |
| RABV | immune escape | 7,220 | Aditham et al. [2025] |
| RABV | cell entry | 8,614 | Aditham et al. [2025] |
| NIPAH | binding | 8,654 | Larsen et al. [2025] |
| NIPAH | immune escape | 8,690 | Larsen et al. [2025] |
| Dataset | Phenotype | Sequences | Reference |
| SCV2 RBD Omicron BA.2 | binding | 4,002 | Starr et al. [2022b] |
| SCV2 RBD Omicron BA.2 | expression | 4,002 | Starr et al. [2022b] |
| SCV2 RBD Omicron BQ.1.1 | binding | 4,203 | Taylor and Starr [2023] |
| SCV2 RBD Omicron BQ.1.1 | expression | 4,202 | Taylor and Starr [2023] |
| SCV2 RBD Omicron XBB.1.5 | binding | 4,212 | Taylor and Starr [2023] |
| SCV2 RBD Omicron XBB.1.5 | expression | 4,212 | Taylor and Starr [2023] |
| Virus | Assays | Substitution | Indel | Combinatorial | Stop/RT | Total |
|---|---|---|---|---|---|---|
| SARS-CoV-2 | 36 | 172,394 | 2,835 | 0 | 0 | 175,229 |
| Influenza A | 17 | 117,674 | 0 | 0 | 0 | 117,674 |
| HIV | 11 | 83,646 | 353 | 0 | 97 | 84,096 |
| Nipah | 3 | 27,434 | 0 | 0 | 0 | 27,434 |
| Zika | 2 | 19,656 | 0 | 0 | 0 | 19,656 |
| Rabies | 2 | 15,834 | 0 | 0 | 0 | 15,834 |
| Binding | Cell entry | Expression | Fitness | Immune escape | Stability | Viral growth | Total | |
|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 | 15 | 4 | 12 | 4 | 1 | 36 | ||
| Influenza A | 2 | 3 | 2 | 10 | 17 | |||
| HIV | 2 | 3 | 6 | 11 | ||||
| Nipah | 1 | 1 | 1 | 3 | ||||
| Zika | 1 | 1 | 2 | |||||
| Rabies | 1 | 1 | 2 |
| Dataset | Sera Source | Subtype | Reference |
|---|---|---|---|
| A/Massachusetts/18/2022 | ferret | H3N2 | Kikawa et al. [2025a] |
| A/Thailand/8/2022 | ferret | H3N2 | Kikawa et al. [2025a] |
| A/DistrictOfColumbia/27/2023 | ferret | H3N2 | Kikawa et al. [2025a] |
| A/Croatia/10136RV/2023-egg | ferret | H3N2 | Kikawa et al. [2025a] |
| A/Netherlands/10563/2023 | ferret | H3N2 | Kikawa et al. [2025a] |
| A/Lisboa/216/2023 | ferret | H3N2 | Kikawa et al. [2025a] |
| Virus | Sub-only tasks | Comb. tasks | Indel/other tasks | Total tasks |
|---|---|---|---|---|
| SARS-CoV-2 | 19 | 0 | 17 | 36 |
| Influenza A | 17 | 0 | 0 | 17 |
| HIV | 6 | 0 | 5 | 11 |
| Nipah | 3 | 0 | 0 | 3 |
| Zika | 2 | 0 | 0 | 2 |
| Rabies | 2 | 0 | 0 | 2 |
| DMS | Neutralisation | GISAID | ||||||
|---|---|---|---|---|---|---|---|---|
| Model Name | Recall | Std. | Spearman | Std. | Spearman | Std. | Recall | Spearman |
| VESPAl | 0.1681 | 0.1279 | 0.2561 | 0.1486 | 0.1965 | 0.2057 | 0.2953 | 0.3158 |
| VESPA | 0.1669 | 0.0971 | 0.2380 | 0.1351 | 0.1965 | 0.2057 | 0.3238 | 0.3616 |
| Tranception S | 0.1603 | 0.0759 | 0.2358 | 0.1381 | 0.1843 | 0.1810 | 0.2370 | 0.2894 |
| Tranception M | 0.1734 | 0.0755 | 0.2654 | 0.1346 | 0.2316 | 0.1696 | 0.3143 | 0.3249 |
| Tranception L | 0.1898 | 0.0857 | 0.2735 | 0.1482 | 0.1927 | 0.1961 | 0.3743 | 0.4014 |
| Model Name | Recall | Spearman | Precision@3 |
|---|---|---|---|
| ProGen2 XL | 0.4077 | 0.3170 | 0.33 |
| ProGen2 BFD90 | 0.3798 | 0.2950 | 0.33 |
| ProGen2 | 0.3794 | 0.3245 | 0.33 |
| Tranception L | 0.3523 | 0.3326 | 0.33 |
| Tranception M | 0.2985 | 0.3217 | 0.33 |
| ProGen2 M | 0.2639 | 0.2428 | 0.00 |
| Model Name | Recall | Improvement (%) | Spearman | Improvement (%) |
|---|---|---|---|---|
| ESM1 670M UR50D | 0.1453 | 4.2070 | 0.1842 | 4.0250 |
| ESM2 3B | 0.1485 | 3.9177 | 0.1890 | 13.9151 |
| VESPAl | 0.1746 | 3.8895 | 0.2586 | 0.9669 |
| ESM2 150M | 0.1351 | 3.8340 | 0.1376 | 20.6038 |
| Tranception S | 0.1662 | 3.6926 | 0.2502 | 6.1056 |
| Tranception L | 0.1964 | 3.4928 | 0.2801 | 2.4001 |
| Top-10% Recall | ||||||
|---|---|---|---|---|---|---|
| Model | Mean | Mean | ||||
| ProGen2 XL (ref) | 0.1973 | — | — | 0.2928 | — | — |
| VESPAl | 0.1682 | 0.0291 | 0.2561 | 0.0367 | ||
| VESPA | 0.1669 | 0.0304 | 0.2380 | 0.0548 | ||
| Tranception S | 0.1603 | 0.0370 | 0.2357 | 0.0571 | ||
| Tranception M | 0.1734 | 0.0239 | 0.2653 | 0.0275 | ||
Protein Language Models
Protein language models learn patterns in amino-acid sequences to predict protein properties, interpret mutations, and design new proteins.
See all 69 papers